eligibility_summary
Eligibility: adults ≥18. BKV/ADV/CMV require prior allo-HSCT, JCV/COVID-19 do not. Infection criteria: BKV PCR+ with symptoms, ADV PCR+ and/or organ disease, CMV PCR+ and/or disease, JCV encephalitis/end-organ disease, COVID-19 pneumonia/ARDS with positive test. Consent incl. long-term, WOCBP: negative test + 2 birth-control methods during and 6 mo after. Exclude: recent ATG/DLI/Campath, uncontrolled infection, steroid-refractory GVHD, other immunosuppression, uncontrolled relapse.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Virus-specific cytotoxic T-lymphocyte (CTL) lines—an adoptive cellular immunotherapy (biologic)—engineered with glucocorticoid receptor (GR/NR3C1) knockout to make cells resistant to steroid-mediated suppression/apoptosis. Mechanism: HLA-restricted recognition of viral epitopes from adenovirus, BK virus, CMV, JC virus, or SARS‑CoV‑2 on infected host cells, followed by CTL killing via perforin/granzyme and antiviral cytokine release, given IV, with repeat dosing permitted. Targets: Virus-infected host cells expressing these antigens. Pathways: TCR signaling and CTL effector pathways are activated, glucocorticoid signaling in the infused T cells is disabled to enhance persistence and function in immunosuppressed cancer patients.